AVP and central nervous system disorder: Considering the wide distribution of peripheral V1AR and V1BR (liver, blood vessel muscles, kidney, heart, platelets, adrenal cortex, pancreas) and the critical responses that can be triggered after the activation or blockade of these targets, there are no AVP therapeutic uses authorized yet for CNS disorders.